WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death*, in people with chronic obstructive pulmonary disease (COPD) who also have elevated cardiopulmonary risk, irrespective of their exacerbation history.1 Also, the first participants have been dosed in ATHLOS, a ...

hapabapa Oncology-focused pharmaceuticals company AstraZeneca PLC (NASDAQ:AZN) has had an underwhelming past year at the stock markets, with just a 3% price rise. However, the limited price change detracts from the fundamental positives of the stock. Here, I look at 5 aspects that set it apart and can provide impetus for price upside in 2024. Price Chart (Source: Seeking Alpha) #1. Improved revenue guidance after an outlook beating 2023 When analyzing any stock, the future financials are, of course, of key ...

The latest trading session saw Astrazeneca (AZN) ending at $66.19, denoting a +1.41% adjustment from its last day's close. The stock's change was more than the S&P 500's daily gain of 1.03%. Meanwhile, the Dow gained 0.34%, and the Nasdaq, a tech-heavy index, added 1.51%.The pharmaceutical's stock has dropped by 1.92% in the past month, falling short of the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca ...

Chancellor Jeremy Hunt also announced that British pharma giant AstraZeneca PLC (LSE:AZN) plans to invest £650 million in UK life sciences. Under levelling-up plans, AstraZeneca will develop a vaccine manufacturing facility in Liverpool. Further details are pending. The announcement came during Hunt's Spring Budget, where he also announced a £5,000 increase in ISA allowances through a ‘Great British ISA’ restricted to UK-listed stocks only. This brings the yearly tax-free allowance for ISA customers up to £ ...

Astrazeneca (AZN) closed at $64.60 in the latest trading session, marking a +0.69% move from the prior day. The stock lagged the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a rise of 0.23%, and the technology-dominated Nasdaq saw an increase of 1.14%.Shares of the pharmaceutical witnessed a loss of 4.02% over the previous month, trailing the performance of the Medical sector with its gain of 3.58% and the S&P 500's gain of 5.2%.The upcoming earnings release of Astrazeneca will be of great i ...

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.A federal judge on Friday rejected AstraZeneca's legal challenge to Medicare's new power to negotiate the prices of certain costly prescription drugs with manufacturers.The decision is another win for the Biden administration in a bitter legal fight with the pharmaceutical industry over the constitutionality of those price talks. The negotia ...

Even after aggressive contractionary monetary policies by the federal reserve, inflation has remained relatively stubborn. Supply-chain issues and an increase in price of agricultural commodities are some factors that have contributed to high inflation. Data from the U.S. indicates that rising rents have contributed to higher inflation in the recent past. With macroeconomic headwinds coupled with inflation, it’s important to hold some inflation-resilient stocks in the portfolio.Inflation-resilient stocks wo ...

Fasenra在EGPA患者中的治疗效果 - Fasenra在EGPA患者中的MANDARA第三期试验取得积极结果，首次展示了超过一半的患者通过嗜酸性粒细胞靶向生物治疗实现缓解[1] - MANDARA试验显示，苯拉珠单抗达到了试验的主要终点，并展示了与美泊利单抗相比的非劣效率[1] - 苯拉珠单抗治疗组患者在48周至52周期间能够完全减少OCS的比例更高，同时在48周至52周期间，86%的苯拉珠单抗患者相比对照组减少了至少50%的OCS剂量[1] Fasenra在EGPA患者中的积极结果 - AstraZeneca的Fasenra在MANDARA Phase III试验中达到了主要终点，对于患有嗜酸性粒细胞性肉芽肿性多发性血管炎（EGPA）的患者产生了积极的高水平结果[26] 其他相关药物治疗效果 - Mepolizumab或安慰剂对于患有嗜酸性粒细胞性肉芽肿性多发性血管炎的患者具有一定的疗效[27] - Benralizumab在中度至非常严重的慢性阻塞性肺疾病（COPD）患者中具有一定的疗效和安全性[28]

阿斯利康股价上涨 - 阿斯利康股价在富时100指数上涨，因为其肺癌药物Tagrisso获得批准[1] Tagrisso治疗效果 - Tagrisso与化疗结合显著延长了中位无进展生存期，针对EGFR突变的非小细胞肺癌患者[3] - 临床试验在全球150多个中心进行，涉及557名患者，展示了治疗的有效性[4]

产品管线风险 - 公司产品管线存在失败或延迟的风险,可能会损害公司的研发能力声誉,并对未来业务和经营业绩产生重大不利影响[11][12] - 产品上市活动可能会因多种因素而延迟,包括临床试验结果、监管要求、价格谈判、自然灾害或全球疫情等,这可能会增加成本并缩短专利保护期[12][13] 监管风险 - 公司需要满足监管机构对药品开发和批准的各种标准,监管政策的变化可能会导致审批延迟,给公司带来额外成本[14][15] 新兴市场风险 - 公司在新兴市场开展业务可能会面临更多挑战,包括经济或政治环境的不稳定性、知识产权保护不力、腐败等[19][20] 价格和销量风险 - 全球经济和政治压力导致各国政府采取更多成本控制措施,如美国通胀减免法案,这可能会对公司产品价格和销量产生不利影响[21] 供应链风险 - 公司依赖第三方供应商,如果供应链出现中断或第三方供应商出现财务问题,可能会影响产品的生产和供应[22][23][24][27] 网络安全风险 - 公司面临网络安全风险,如系统故障、数据泄露等,可能会对公司声誉和财务状况造成重大不利影响[32][33][34] 第三方服务管理风险 - 公司依赖大量第三方服务,如果无法有效管理这些供应商,可能会导致业务中断,影响公司的运营和财务业绩[29][30][31] 数据隐私和人工智能风险 - 公司需要严格遵守各国有关数据隐私和人工智能的法规要求,否则可能会受到监管处罚并损害公司声誉[40] - 人工智能技术可能会加剧现有的数据隐私、网络安全和知识产权等风险,并引入新的风险,如放大偏见和歧视性决策、不可靠和故障、难以解释的洞见以及对个人或群体造成直接伤害[45] 意外事件风险 - 意外事件和不可控因素,如地缘政治冲突、自然灾害等,可能会导致公司关键业务流程失败,从而影响收入和财务业绩[36][37][38] 人才管理风险 - 公司面临吸引、发展、参与和留住多样化、有才能和能力的员工的挑战,这可能会削弱关键职位的继任计划,影响战略目标的实施,并最终导致业务运营失败[47] 环境风险 - 公司面临环境问题带来的监管风险和商业劣势,包括气候变化对业务运营和供应链韧性的影响[48][49][50][51][52] 产品安全性风险 - 产品安全性问题和不利事件可能导致产品召回、销售下降和供应中断,从而严重影响患者获取、声誉和财务收入[53][54] 公司历史 - 公司于1999年通过与瑞典公司Astra的合并而成立[75] - 2021年收购了罕见病业务公司Alexion[75] 研发管线 - 公司目前拥有丰富的研发管线，涵盖肿瘤、心血管肾脏代谢、呼吸免疫等多个治疗领域[77][78] - 公司正在开发针对多发性骨髓瘤、B细胞非霍奇金淋巴瘤、急性髓系白血病等多种肿瘤的新药[77] - 公司正在开发针对非酒精性脂肪肝炎、心力衰竭等代谢性疾病的新药[78] - 公司正在开发针对哮喘、特发性肺纤维化等呼吸免疫疾病的新药[78] - 公司正在开发针对阿尔茨海默病、帕金森病等神经系统疾病的新药[78] - 公司正在开发针对罕见病如肾病、肌无力综合征等的新药[78] - 公司正在开发新冠疫苗[77] - 公司正在开发多种免疫细胞治疗新药[77] - 公司正在开发MET抑制剂Orpathys,并与Imfinzi(PD-L1单抗)联合用于一线治疗乳头状肾细胞癌[81] - 公司正在开发Tagrisso(EGFR抑制剂)与化疗联合用于一线治疗晚期EGFR突变非小细胞肺癌[80] - 公司正在开发Tagrisso(EGFR抑制剂)与Orpathys(MET抑制剂)联合用于治疗EGFR突变非小细胞肺癌[80] 主要产品 - 公司主要产品包括Calquence、Enhertu、Faslodex、Imfinzi、Imjudo、Iressa、Lynparza、Orpathys、Tagrisso和Truqap等[82] - 公司主要产品专利到期时间分布在2022年至2037年之间[83] - Tagrisso是公司主要的EGFR抑制剂产品,2023年全球销售额达到57.99亿美元[82] - Lynparza是公司主要的PARP抑制剂产品,2023年全球销售额达到28.11亿美元[82] - Imfinzi是公司主要的PD-1/PD-L1抑制剂产品,2023年全球销售额达到40.19亿美元[82] 新产品管线 - 公司正在开发多个新产品管线,包括针对NSCLC、前列腺癌、乳腺癌等适应症的靶向治疗药物[82] - 公司正在开发针对心血管、呼吸和免疫等领域的新产品,如Farxiga、Breztri、Fasenra等[82] - 公司正在开发针对罕见病领域的新产品,如Ultomiris等[82] - 公司正在开发多个新产品管线,涉及多种机制作用,包括EGFR抑制剂、MET抑制剂、AKT抑制剂等[82] - 公司正在开发多个